Loading market dashboard
Canopy Growth Corporation
CGCHealthcareNASDAQCA
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Canopy Growth (CGC) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Canopy Growth diluted existing shareholders to pull off a recent acquisition. It is now the top medical cannabis company by revenue in Canada.
Those who have been investing in marijuana stocks over the years have seen many changes. If you have been investing and trading since just before the pandemic, then you know how exciting the sector can be. With all the changes in the cannabis industry, from regulations to federal legislation, hopes are high for investors. At the start, some were filled with doubt about legal cannabis, let alone investing in marijuana stocks.
The latest trading day saw Canopy Growth Corporation (CGC) settling at $1.06, representing a -1.85% change from its previous close.
Several key metrics point to improving fundamentals.
Medical marijuana was moved to the DEA's Schedule III from Schedule I. This confers some accounting advantages, at best, and the company can't even capitalize on them yet.
SMITH FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) today announced the relaunch of the Tweed brand in the German medical market, alongside the introduction of three cannabis strains developed by MTL Cannabis Corp. (“MTL”), a wholly-owned subsidiary of the Company. The dual milestone represents the Company's first international product release following its recent acquisition of MTL. The Tweed brand relaunch – now powered.
Canopy Growth Corporation (âCanopy Growthâ or the âCompanyâ) (TSX: WEED) (Nasdaq: CGC) today announced the relaunch of the Tweed brand in the German me
The Canadian cannabis sector continues showing signs of long-term potential heading into June 2026. Several companies are expanding globally while improving operational efficiency. In addition, many cannabis investors are watching for future developments in the United States' reform. Those possible reforms could create new growth opportunities across the industry. However, volatility remains high in cannabis stocks. Because of this, traders should continue using technical analysis and proper risk management strategies. Strong balance sheets and improving revenue trends are becoming increasingly important for investors. Furthermore, companies with diversified operations may perform better during uncertain market conditions. Three Canadian cannabis companies continue attracting investor attention this month. These companies include TLRY, CGC, and VFF.
In the latest trading session, Canopy Growth Corporation (CGC) closed at $1.07, marking a +1.9% move from the previous day.
Canopy Growth is an important player in the marijuana sector. The stock is trading in penny-stock territory.
Canopy Growth gains attention as marijuana reclassification boosts cannabis sentiment, but margin pressure and execution risks persist.
The company has struggled to improve its business -- and especially to earn a profit. It also has a habit of making dilutive secondary share issues.
Canopy Growth (CGC) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Canopy Growth Corporation (CGC) closed the most recent trading day at $0.98, moving 5.55% from the previous trading session.
SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) expects to release its financial results for the quarter and fiscal year ended March 31, 2026 before financial markets open on June 15, 2026. The Company also announced it plans to file restated financial results for the fiscal years ended March 31, 2025 and March 31, 2024 and to certain of the interim periods therein (the “Refiling”), in conjunction with its filing of.
Canadian cannabis stocks remain active in May 2026. Investors continue watching the sector for growth opportunities and reform catalysts. In addition, many traders expect future federal progress in the United States. That possibility has increased interest across the entire cannabis market. Recent headlines surrounding possible cannabis rescheduling also boosted momentum in leading names.
Investors are no longer buying a hypergrowth cannabis stock. They're betting on a turnaround story.
Canopy Growth Corporation (CGC) closed at $1.1 in the latest trading session, marking a -1.79% move from the prior day.
SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) and Spectrum Therapeutics today announced an expansion of its Minor Cannabinoid softgel lineup, introducing new 30 and 90-pack formats and additional dosing options across its Optimized Spectrum portfolio. The expansion builds on the strong performance of existing 30-pack formats and reflects Canopy Growth's ongoing commitment to improving patient access through targete.
Recently, Zacks.com users have been paying close attention to Canopy Growth (CGC). This makes it worthwhile to examine what the stock has in store.
Canopy Growth Corporation (CGC) reached $1.11 at the closing of the latest trading day, reflecting a +1.83% change compared to its last close.
Sin stocks attract investors for inelastic demand, steady cash flows, dividends and pricing power, often at lower valuations when excluded by ESG rules.
The Canadian cannabis sector continues to evolve as investors look for the next major catalyst. Recently, optimism has increased around potential U.S. cannabis reform. As a result, many Canadian companies could benefit from future expansion opportunities. Additionally, these companies already trade on major exchanges, giving them broader access to investors. However, volatility still remains across the sector. Therefore, using technical analysis and managing risk is critical when trading these stocks.
The pot stock is up over 30% in just the past month.
Canopy Growth Corporation (CGC) concluded the recent trading session at $1.19, signifying a -2.87% move from its prior day's close.
Canopy Growth is a penny stock, so small price movements can lead to huge percentage changes. The marijuana company recently bought another company, extending its reach in medical marijuana.
Top insights from the latest market news from Friday, April 24, from The Motley Fool analysts on Team Rule Breakers and Team Hidden Gems.
Intel results show strong AI demand, cannabis stocks slump after DOJ ruling, and more
Marijuana-related investments were flying high this morning. Then they reversed course, and quickly.
Markets don't usually wait for permission — they anticipate it.
Canopy Growth Corp (NASDAQ: CGC) shares are falling Thursday, pulling back after Wednesday's rally on U.S. cannabis policy shift.
SMITH FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth”, “Canopy” or the “Company”) (TSX: WEED) (Nasdaq: CGC) today announced a refresh of Tweed, one of Canada's most recognizable cannabis brands, alongside a national summer campaign, “There's a Tweed for That.” In the Canadian flower category, consumers have had to commit to products they couldn't see. New window bags for Tweed's flower SKUs closes that gap, giving consumers a clear view of what they are buying, with.
Shares of Canopy Growth Corp (NASDAQ:CGC) are trading sharply higher Wednesday afternoon following news of a potential major shift in federal cannabis policy. Here's what investors need to know.
Canopy Growth (CGC) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Canopy Growth has lost more than 99% of its value during the past five years. A partial rebound may be possible, but don't discount the risk of long-standing issues placing additional pressure.
In the latest trading session, Canopy Growth Corporation (CGC) closed at $1.14, marking a -5% move from the previous day.
Marijuana stock investors are still in a position where volatility and speculation control the outcome. Especially with all the laws and regulatory changes that have transformed the cannabis industry. All of which has an impact on how the public sector behaves. When an investor speculates, whether for better or worse, it can lead to others following suit, and this typically creates more momentum for the sector as a whole. As the current state of the cannabis sector has not changed much in this regard, investors are keeping a close eye on any upward shifts in trading.
In the latest trading session, Canopy Growth Corporation (CGC) closed at $1.08, marking a +2.86% move from the previous day.
Marijuana stock investors who have been trading and holding over the years know this sector holds potential. Now, potential doesn't put money in your pocket, but progressive and profitable companies that make up the industry can, which means that there is a lot of potential to see big gains in the future with all that is taking place. For the USA, there are only a few states that have yet to legalize cannabis. Just the legal states alone in 2026 have brought in a billion in revenue.
Recently, Zacks.com users have been paying close attention to Canopy Growth (CGC). This makes it worthwhile to examine what the stock has in store.
In the latest trading session, Canopy Growth Corporation (CGC) closed at $1.02, marking a +2% move from the previous day.
The Canadian cannabis sector continues evolving as global opportunities expand. Many companies are now positioning for U.S. entry. Additionally, federal reform discussions in the United States remain a major catalyst. As a result, investors are closely watching key Canadian names. However, volatility remains high, so proper risk management is essential.
SMITH FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) today announced Deelish ("DEE-LISH"), a new cannabis brand built for the everyday consumer with an everyday price. Deelish enters the market built to deliver high THC with flower testing at 27%-33% THC and pre-rolls at 26%-32% THC. And unlike brands built around a single profile, Deelish rotates its genetic lineup regularly, giving consumers access to a curated range of.
Marijuana legalization in the U.S. isn't likely to happen anytime soon, and that's weighing on Canopy Growth's stock. The company's results have been abysmal, and there's little reason to be optimistic that they'll improve anytime soon.
SMITH FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) today announced that its Apollo Cannabis Clinics (“Apollo”) has been named Best Medical Cannabis Clinic in the 2025 Toronto Star's Readers' Choice Awards, a public vote that reflects the trust patients place in Apollo's care. Apollo represents the Company's commitment to raising the standard of medical cannabis and making quality treatment accessible to every Canadian. “.
SMITH FALLS, Ontario & TUTTLINGEN, Germany--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) today announced the appointment of David Männer as Managing Director of Storz & Bickel, a subsidiary of Canopy Growth, effective April 1, 2026. Mr. Männer succeeds Jürgen Bickel, Storz & Bickel's Co-founder, who has decided to transition out of his role. Founded in 2001, Storz & Bickel has grown into a global leader in vaporization techn.
Recently, Zacks.com users have been paying close attention to Canopy Growth (CGC). This makes it worthwhile to examine what the stock has in store.
These two companies are facing nearly insurmountable challenges. Their share prices could keep on dropping over the medium term.
SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Completes Acquisition of MTL Cannabis Creating Canada's Leading Medical Cannabis Business By Revenue.
Recently, Zacks.com users have been paying close attention to Canopy Growth (CGC). This makes it worthwhile to examine what the stock has in store.
The global cannabis industry continues evolving as legalization slowly expands across multiple regions. Investors remain focused on companies positioned for long-term growth. Canadian cannabis producers still play a major role in this global expansion.
Canopy Growth has struggled to generate much growth in recent years. It has continued to incur significant losses and burn through a ton of cash.
Canopy Growth is a marijuana stock trading around $1 a share. The company is acquiring another marijuana business in a cash-and-stock transaction.
